Adaptimmune Therapeutics
-
Roche bets $300M on Adaptimmune tech for off-the-shelf cell therapies for cancer
Roche is partnering with Adaptimmune Therapeutics to develop allogeneic cell therapies based on Adaptimmune’s technology. In addition to these “off-the-shelf” products, the partners will also develop a personalized allogeneic cell therapy designed specifically for a patient’s cancer.
-
Astellas partners with Adaptimmune in latest move into cell therapy
The companies will work to develop allogeneic CAR-T and T-cell receptor therapies. Astellas has made multiple moves into cell and gene therapy in the past month.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.